Thus, besides the already known increased synthesis and binding capacity of SHBG in mitotane-exposed ACC patients, here we provided robust evidence demonstrating that the estrogen-like effects observed in the clinic are due to the direct capability of mitotane to bind and activate ER-α. Here, ESR1 is linked to adrenal cortex carcinoma.